http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GB-1377034-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c999fee6428152a996011d506925c2d7 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H1-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-20 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H1-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F9-6506 |
| filingDate | 1973-02-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 1974-12-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | GB-1377034-A |
| titleOfInvention | Nucleoside-5,-diphosphate derivatives and process for producing the same |
| abstract | 1377034 Nucleoside-5<SP>1</SP>-diphosphate derivatives AJINOMOTO CO Inc 21 Feb 1973 [23 Feb 1972] 8603/73 Heading C2P Compounds of Formula I and salts thereof, where R is a 51-nucleoside radical and R<SP>1</SP>, R<SP>2</SP> and R<SP>3</SP> are hydrogen or C 1-4 alkyl, including the novel compounds of Formula III: and salts thereof, where R<SP>4</SP> is the 5<SP>1</SP>-nucleoside radical of inosine, 5-amino-1-ribofuranosylimidazole - 4 - carboxamide, N<SP>1</SP> - methylinosine, 2- methylinosine, 6 - thioinosine, 2 - methylthioinosine or N<SP>2</SP> - methylguanosine, are prepared by reacting a nucleoside-5<SP>1</SP>-monophosphate of formula R-PO 3 H 2 or a salt thereof with a compound of Formula II: or a salt thereof in the presence of, as condensing agent, an s-triazine derivative selected from cyanuric chloride, 2-amino-4,6-dichloro-s-triazine, 2 - hydroxy - 4,6 - dichloro - s - triazine, 2 - ethoxy - 4,6 - dichloro - s - triazine, 2,4 - dipyridino - 6 - chloro - s - triazine and 2,4 - diamino - 6 - chloro - s - triazine until the desired product is formed. In addition to the 51-nucleosides set out above, R may also be derived from adenosine, guanosine, N<SP>2</SP>,N<SP>2</SP>- dimethylguanosine, N<SP>6</SP> - methyladenosine, N<SP>6</SP>,N<SP>6</SP> - dimethyladenosine, cytidine, uridine, deoxycytidine, deoxyuridine, 1-beta-D- arabinofuranosyluracil or N-succinyl-5-amino-1- ribofuranosylimidazole-4-carboxamide. The reaction may be carried out in a solvent medium selected from formamide, dimethyl formamide, o-chlorophenol, acetonitrile, triethyl phosphate and pyridine. The condensing agent is preferably cyanuric chloride and may be present in an amount of 1À5 to 5 moles per mole of nucleoside- 5<SP>1</SP>-monophosphate. The compounds of Formula I have pharmaceutical properties. |
| priorityDate | 1972-02-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 75.